RxDoctor Payments Data

Richard Basham

Family · Leitchfield, KYNPI 1588921738

Payments from drug & device makers

$837in general payments, 2019–2025

Across 53 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$274
  • Vanda Pharmaceuticals Inc.$143
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109
  • Axsome Therapeutics, Inc.$65
  • Pfizer$54
  • Alkermes, Inc.$49
  • plus $144 from 7 others

What the payments were for

  • Food & beverage$837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$837 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$18,756
Medicare patients
77
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$57,892
EliquisApixaban54$39,552
LinzessLinaclotide53$33,955
MounjaroTirzepatide31$33,366
OzempicSemaglutide29$32,566
VraylarCariprazine Hcl20$29,110
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$26,743
XareltoRivaroxaban22$25,985
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$24,202
UbrelvyUbrogepant18$18,349
JardianceEmpagliflozin27$18,165
QuliptaAtogepant15$15,767
Nurtec OdtRimegepant Sulfate15$14,996
TrintellixVortioxetine Hydrobromide24$11,558
EntrestoSacubitril/Valsartan11$8,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Vraylar, Ubrelvy, Qulipta$274$97,181106 claims
PfizerEliquis, Nurtec Odt$54$54,54969 claims
GSKAnoro Ellipta, Trelegy Ellipta$11$50,94584 claims
Lilly USA, LLCMounjaro, Cymbalta, Olanzapine$14$39,22156 claims
Johnson & JohnsonXarelto$23$25,98522 claims
AstraZenecaSymbicort$18$6,31828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Leitchfield

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →